All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-ErbB2 (HER2) chimeric antigen receptor(CAR) is constructed for the engineering of NK cell to target human ErbB2. The NK cell is genetically modified through transduction with a lentiviral vector expressing scFv of anti-ErbB2 antibody linked to CD3-zeta signaling domains. And the vector product was designed for the treatment of breast carcinomas, ovarian carcinoma .
CAR Construction : FRP5 scFv-41BB-CD28ζ Fig.1 Secretion of tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) by CAR T cells assessed by cytometric bead array after 24 h exposure to synovial sarcoma cells. HER2-targeted CAR T cells (blue bars) produced significantly higher levels of TNF-α and IFN-γ than T cells transduced with the empty vector (mock; orange bars). Data are presented as the mean ± standard deviation (SD) of triplicate experiments. The data are representative results from experiments using at least 2 healthy donors. ***P < 0.001. Murayama, Y., Kawashima, H., Kubo, N., Shin, C., Kasahara, Y., Imamura, M., Oike, N., Ariizumi, T., Saitoh, A., Mihara, K., Umezu, H., Ogose, A., & Imai, C. (2021). Effectiveness of 4-1BB-costimulated HER2-targeted chimeric antigen receptor T cell therapy for synovial sarcoma. Translational oncology, 14(12), 101227. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-ErbB2 scFv h(CD3ζ) CARNK, pCDCAR1 (CAR-NK-1-M331-Z). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION